¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"thyroid carcinoma risk factors"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
¿µ¹® thyroid carcinoma ÇÑ±Û °©»ó»ù¾ÏÁ¾
¼³¸í   
  °©»ó»ù¿¡ »ý±ä »óÇǼ¼Æ÷·Î ÀÌ·ç¾îÁø ¾Ç¼ºÁ¾¾ç¹°. º´¸®Á¶Á÷ÇÐÀûÀΠÇüÅ¿¡ µû¶ó À¯µÎ»ó, ¼ÒÆ÷»ó, ¿ªÇü¾ÏÁ¾ ¹× ¼öÁú¾ÏÁ¾, ¸²ÇÁÁ¾ µîÀ¸·Î ³ª´­ ¼ö ÀÖ´Ù. ´Ù¾çÇÑ ¿øÀÎÀÌ ÀÖÀ¸³ª, ÀϺο¡¼­´Â ¹æ»ç¼±Æø·Î¿¡ ÀÇÇØ ¹ß»ýÇÑ´Ù. Ä¡·á´Â ¼ö¼ú, ¹æ»ç¼º ¿Á¼Ò, T4 ¾ïÁ¦¿ä¹ý µîÀÌ »ç¿ëµÈ´Ù.
¿µ¹® risk factor ÇÑ±Û À§ÇèÀÎÀÚ
¼³¸í   
  ±¹Á¦¹æ»ç¼±¹æÈ£À§¿øÈ¸(ICRP)°¡ 1977³â ±Ç°í¿¡¼­ ¹æ»ç¼±¹æÈ£ÀÇ ¸ñÀûÀ¸·Î Ã¤ÅÃÇÑ Áö¼ö·Î, ´ÜÀ§¼±·®(1 Sv)´ç È®·üÀû ¿µÇâÀÇ ¹ß»ýÈ®·üÀ» ÃßÁ¤ÇÏ¿© ³ªÅ¸³½ °ÍÀÌ´Ù. »ý½Ä¼± ¼±·®¿¡ ´ëÇÑ À¯ÀüÀû¿µÇâÀÇ ¹ß»ý·ü(4¡¿10£­3/Sv)À̳ª Àû»ö°ñ¼ö¼±·®¿¡ ´ëÇÑ ¹éÇ÷º´ ¹ß»ý·ü(2¡¿10£­3/Sv)µî ¿Ü¿¡ »À, ÇãÆÄ, °©»ó»ù, Á¥»ù, ±âŸ Á¶Á÷ÀÇ À§ÇèÁö¼ö¸¦ ÃøÁ¤ÇÏ¿©, È®·üÀû ¿µÇâÀÇ Àü½Å¿¡ À־ Ä¡»çÀ§ÇèÁö¼öÀÇ Çհ踦 16.5¡¿10£­3/Sv·Î ÇÏ¿´´Ù. ±×ÈÄ ICRP´Â 1990³â ±Ç°í¿¡¼­ ´ë»óÀÌ µÇ´Â Á¶Á÷°ú Àå±â¸¦ Ãß°¡Çϰí, ¼öÄ¡ °³Á¤À» Çϸ鼭 ¸íεµ °¢¸ñÀûÈ®·üÁö¼ö¶ó°íÇÏ¿´´Ù. ÀÌ ±Ç°í¿¡ ÀÇÇϸé, Ä¡»çÀû È®·üÀû ¿µÇâÀÇ È®·üÁö¼öÀÇ ÇÕ°è´Â, ÀϹÝÀο¡ ÀÖ¾î 60.0¡¿10£­3/SvÀÌ´Ù.
¿µ¹® thyroid gland ÇÑ±Û °©»ó»ù
¼³¸í   
  »ç¶÷ÀÇ ¸ö¿¡¼­ °¡Àå Å« ³»ºÐºñ»ùÀ¸·Î ¸ñÀÇ ¾ÕÂÊ, ¾Æ·¡ÂÊ¿¡ À§Ä¡Çϰí ÀÖÀ¸¸ç 2¿±À¸·Î ±¸¼ºµÇ¾î ÀÖ´Ù. °¢ ¿±Àº ±â°üÀÇ ¾çÂÊ¿¡ ÀÖÀ¸¸ç Á¼Àº Àß·è¿¡ ÀÇÇØ ¾Õ¿¡¼­ ¿¬°áµÇ¾î ÀÖ´Ù. °©»ó»ùÈ£¸£¸óÀΠƼ·Ï½Å(thyroxine)À» ºÐºñÇϰí ÀúÀåÇϸç, Çʿ信 µû¶ó ¹æÃâÇÑ´Ù. ¶ÇÇÑ °©»ó»ùÀº Æ¼·ÎÄ®½ÃÅä´Ñ(thyrocalcitonin)µµ ºÐºñÇÑ´Ù. º´ÀûÀΠ»óÅ¿¡¼­ Å©±â°¡ ´ë°³ Áõ°¡Çϰí, ÀϺο¡¼­´Â µµ¸®¾î À§ÃàµÇ¸ç, ÅëÁõÀ» ³ªÅ¸³»±âµµ ÇÑ´Ù.
¿µ¹® thyroid hormone ÇÑ±Û °©»ó»ùÈ£¸£¸ó
¼³¸í   
  ±¤ÀÇÀÇ °©»ó¼±È£¸£¸óÀº Æ¼·Ï½Å(thyroxine(T4)), »ï¿äµåƼ·Î´Ñ(triiodothyronine (T3)), Æ¼·ÎÄ®½ÃÅä´Ñ(thyrocalcitonin)ÀÇ 3°¡ÁöÁß Çϳª¸¦ ¸»Çϳª ´ë°³ÀÇ °æ¿ì ÇùÀÇÀÇ ¶æÀ¸·Î »ç¿ëµÇ¸ç ÀÌ °æ¿ì Æ¼·Ï½Å°ú »ï¿äµåƼ·Î´ÑÀ» ÁöĪÇÑ´Ù.
  
  °©»ó¼± È£¸£¸óÀº °ÅÀÇ ¸ðµç ¸ö¼¼Æ÷¿¡¼­ÀÇ ¹ÙÅÁÁú´ë»ç¿¡ °ü¿©ÇÏ¿© ¿¡³ÊÁö»ý¼ºÀ» Áõ°¡½ÃŰ°í ¼ºÀå ¹ßÀ°À» ÃËÁøÇÑ´Ù.
  
  À̰ÍÀº ³úÇϼöü¿¡¼­ ºÐºñµÇ´Â °©»ó»ù ÀÚ±ØÈ£¸£¸ó¿¡ ÀÇÇØ ÇÕ¼º ¹× ºÐºñ°¡ ÃËÁøµÈ´Ù. ¼·ÃëÇÏ¿© Ã¼³»¿¡ µé¾î¿Â ¿ä¿Àµå°¡ ´Éµ¿¿î¹Ý¿¡ ÀÇÇØ °©»ó»ù¼¼Æ÷³»·Î µé¾î°¡ ¼¼Æ÷³»¿¡ Àִ ´Ü¹éÁúÀΠ°©»ó»ù ±Û·Îºí¸°°ú °áÇÕÇÏ¿© °©»ó»ùÈ£¸£¸óÀ¸·Î ÇÕ¼ºµÈ´Ù. ¿ä¿Àµå°¡ 3ºÐÀÚ °áÇÕÇÑ °ÍÀ» T3, 4ºÐÀÚ °áÇÕÇÑ °ÍÀ» T4¶ó ºÎ¸§. ºÐºñµÇ´Â °©»ó¼± È£¸£¸óÁß 90%ÀÌ»óÀÌ T4ÀÌ´Ù. Ç÷ÁßÀ¸·Î ºÐºñµÈ °©»ó»ùÈ£¸£¸óÀº Ç÷Áß ´Ü¹éÁú°ú °áÇÕÇϴµ¥ ´ëºÎºÐÀº Æ¼·Ð½Å°áÇÕ±Û·Îºí¸°°ú °áÇÕÇϸç ÀϺδ ¾ËºÎ¹Î°ú °áÇÕÇÑ´Ù.
  
  Àü¹ÝÀûÀΠ´ë»çÀ²À» ÃËÁø½ÃŰ¸ç ¾î¸°ÀÌ¿¡¼­´Â ¼ºÀåÀ» ÃËÁø½ÃŲ´Ù. Æ¯È÷ ¾î¸°ÀÌ¿¡¼­ ¸ô´Ü¹éÁú ÇÕ¼ºÀ» ÃËÁøÇϸ砳úÀÇ ¹ß´Þ¿¡ Áß¿äÇÑ ±â´ÉÀ» ÇÔÀ¸·Î½á, ¼±Ãµ¼º °©»ó»ùÀúÇÏÁõ(cretinism)À» Á¶±â ¹ß°ßÇÏ¿© Ä¡·áÇÏÁö ¸øÇϸé Á¤½ÅÁöü°¡ À¯¹ßµÈ´Ù. °©»ó»ù°ú´ÙÁõÀÇ Áõ»óÀº Ã¼³» ´ë»ç°¡ Ç×ÁøµÇ¾î ½Ä¿åÀÌ Áõ°¡Çϳª Ã¼ÁßÀÌ °¨¼ÒÇÏ°í ½ÉÀå¹Úµ¿¼ö°¡ Áõ°¡Ç졒ʫõÀ§¸¦ ÂüÁö ¸øÇϸç, °©»ó»ù±â´ÉÀúÇÏÁõÀÇ Áõ»óÀº À§¿Í ¹Ý´ë·Î ½Ä¿åÀÌ °¨¼ÒÇϰí Ã¼ÁßÀÌ Áõ°¡Çϸ砽ÉÀå¹Úµ¿¼ö°¡ °¨¼ÒÇϰí ÃßÀ§¸¦ ÂüÁö ¸øÇϸç ÇǺο¡ ´Ü¹éÁúÀÌ ÃàÀûµÇ¾î Á¡¾×ºÎÁ¾ÀÌ À¯¹ßµÈ´Ù.
¿µ¹® bronchogenic carcinoma ÇÑ±Û ±â°üÁö¿ø¼º ¾ÏÁ¾
¼³¸í   
  ÆóÀÇ ±â°üÁö ¼¼Æ÷¿¡¼­ ±â¿øÇϴ Á¾¾ç. Æó¾ÏÀÇ Á¾·ù¿¡¼­ °¡Àå ÈçÇÑ ÇüÅÂ(90%ÀÌ»ó)ÀÌ´Ù. Çö¹Ì°æÀû ¼Ò°ß¿¡ µû¶ó »ù¾ÏÁ¾, Å«¼¼Æ÷¾ÏÁ¾, ¼Ò¼¼Æ÷(ÀÛÀº¼¼Æ÷) ¾ÏÁ¾ÀÇ 4°¡Áö·Î ³ª´«´Ù. ÀÌÁß¿¡¼­ ÆíÆò¼¼Æ÷¾ÏÁ¾ÀÌ °¡Àå ÈçÇÑ ÇüÅÂÀÌ´Ù. ÀÓ»óÀûÀ¸·Î´Â ºñ¼Ò¼¼Æ÷Æó¾Ï(non-small cell lung cancer)¿Í ¼Ò¼¼Æ÷Æó¾Ï(small cell lung cancer)·Î ±¸ºÐÀ» Çϴµ¥, ºñ¼Ò¼¼Æ÷Æó¾ÏÀÇ °æ¿ì Á¾¾ç¼¼Æ÷ÀÇ ¼ºÀåÀÌ ´À¸®°í ¼ö¼úÀû Á¦°Å°¡ Ä¡·áÀÇ ±âº»ÀÌ µÇ°í ¿¹Èĵµ ÁÁÀº ¹Ý¸é, ¼Ò¼¼Æ÷Æó¾ÏÀÇ °æ¿ì¿¡´Â ¾Ï¼¼Æ÷ÀÇ ¼ºÀåÀÌ ¸Å¿ì ºü¸£°í Ä¡·áµµ ¹æ»ç¼±Ä¡·á¸¦ ±âº»À¸·Î Çϸ砿¹Èĵµ ºñ¼Ò¼¼Æ÷Æó¾Ï¿¡ ºñÇØ¼­ ÁÁÁö°¡ ¸øÇÏ´Ù.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • papillary thyroid carcinoma
    À¯µÎ°©»ó»ù¾ÏÁ¾, À¯µÎ°©»ó¼±¾ÏÁ¾
  • accessory thyroid
    µ¡°©»ó»ù
  • accessory thyroid gland
    µ¡°©»ó»ù
  • aberrant thyroid
    µý°÷°©»ó»ù, À̼Ҽº°©»ó¼±
  • ectopic thyroid
    µý°÷°©»ó»ù, À̼Ҽº°©»ó¼±
  • functioning thyroid nodule
    ±â´É°©»ó»ù°áÀý
  • lingual thyroid
    Çô°©»ó»ù
  • long-acting thyroid stimulator
    Áö¼Ó°©»ó»ùÀڱع°Áú, Áö¼Ó°©»ó¼±Àڱع°Áú
  • nonfunctioning thyroid nodule
    ºñ±â´É°©»ó»ù°áÀý
  • superior thyroid artery
    À§°©»ó»ùµ¿¸Æ, »ó°©»ó¼±µ¿¸Æ
  • attributable risk
    ±âÀÎÀ§Çèµµ
  • absolute risk model
    Àý´ëÀ§Çè¸ðÇü
  • behavioral risk factor
    ÇൿÀ§Çè¿äÀÎ
  • empiric risk
    °æÇèÀûÀ§Çèµµ
  • high risk group
    °íÀ§Ç豺
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • papillary thyroid carcinoma
    À¯µÎ°©»ó»ù¾ÏÁ¾
  • risk factor
    À§ÇèÀÎÀÚ
  • high risk group
    °íÀ§Ç豺
  • low risk group
    ÀúÀ§Ç豺
  • risk
    À§Çè, À§Çèµµ
  • attributable risk
    ±â¿©À§Çèµµ
  • relative risk
    ºñ±³À§Çèµµ
  • surgical risk
    ¼ö¼úÀ§Çèµµ
  • thyroid cartilage
    ¹æÆÐ¿¬°ñ, °©»ó¿¬°ñ
  • thyroid papillary cancer
    °©»ó»ùÀ¯µÎ¾ÏÁ¾
  • thyroid follicle
    °©»ó»ù¼ÒÆ÷
  • thyroid gland
    °©»ó»ù
  • thyroid stimulating hormone
    °©»ó»ùÀÚ±ØÈ£¸£¸ó
  • cold thyroid nodule
    ºñ±â´É°©»ó»ù°áÀý
  • thyroid
    °©»ó»ù
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • aberrant thyroid
    µý°÷¹æÆÐ»ù, À̼Ұ©»ó»ù
  • accessory thyroid
    µ¡¹æÆÐ»ù, µ¡°©»ó»ù
  • accessory thyroid gland
    µ¡°©»ó»ù, µ¡¹æÆÐ»ù
  • thyroid acropathy
    ¹æÆÐ»ù¸»´Üºñ´ëÁõ, °©»ó»ù¸»´Üºñ´ëÁõ
  • thyroid adenoma
    ¹æÆÐ»ùÁ¾, °©»ó»ùÁ¾
  • thyroid artery
    °©»óµ¿¸Æ
  • cold thyroid nodule
    ºñ±â´É°©»ó»ù°áÀý
  • thyroid cartilage
    ¹æÆÐ¿¬°ñ, °©»ó¿¬°ñ
  • thyroid colloid
    ¹æÆÐ»ùÄÝ·ÎÀ̵å, °©»ó»ùÄÝ·ÎÀ̵å
  • thyroid crisis
    °©»ó»ùÁßµ¶¹ßÀÛ
  • thyroid hormone deficiency
    ¹æÆÐ»ùÈ£¸£¸ó°áÇÌ, °©»ó»ùÈ£¸£¸ó°áÇÌ
  • functioning thyroid nodule
    ±â´É°©»ó»ù°áÀý
  • thyroid follicle
    °©»ó»ù¼ÒÆ÷, ¹æÆÐ»ù¼ÒÆ÷
  • thyroid gland
    °©»ó»ù, ¹æÆÐ»ù
  • thyroid-stimulating hormone
    (¢¡thyrotropin) ¹æÆÐ»ùÀÚ±ØÈ£¸£¸ó, °©»ó»ùÀÚ±ØÈ£¸£¸ó
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • Insulin-like growth factors
    Àν¶¸°¾ç(å×)¼ºÀå(à÷íþ)È£¸£¸ó
  • psychological factors affecting medical condition
    ÀÇÇÐÀû»óÅ¿¡ ¿µÇâÀ» ÁÖ´Â ½É¸®Àû ¿ä¼Ò.
  • psychological factors affecting physical condition
    ½Åü»óÅ¿¡ ¿µÇâÀ» ÁÖ´Â ½É¸®Àû ¿ä¼Ò.
  • quality factors
    Ư¼º ¿ä¼Ò, Áú ¿ä¼Ò
  • absolute risk
    Àý´ëÀ§Çè
  • absolute risk model
    Àý´ëÀ§Çè¸ðµ¨
  • acceptable risk
    ¿ëÀÎÀ§Çèµµ, ¼ö¿ëÀ§Çèµµ
  • anesthetic risk
    ¸¶ÃëÀ§Çèµµ.
  • high risk group
    °íÀ§Çèµµ±º(Ë­Ëô̴̬˴).
  • high risk infant
    °íÀ§Ç輺 ¿µ¾Æ.
  • physical hazard =p. risk
    ½ÅüÀû À§Çè (ÊÙËøËôÌ´).
  • physical risk =physical hazard
    ½ÅüÀû À§Çè(µµ)(ËàÌ§ËøËô̴̬)
  • radiation risk
    ¹æ»ç¼±À§ÇØ, ¹æ»ç¼± À§Çè
  • radiation risk coeffecient
    ¹æ»ç¼±À§ÇèÁö¼ö
  • recurrence risk
    Àç¹ßÀ§Çè
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • risk factors
  • carcinoma of thyroid, papillary
    °©»ó¼± À¯µÎ»ó¾ÏÁ¾
  • papillary carcinoma of thyroid
    °©»ó¼± À¯µÎ¾Ç¼ºÁ¾¾ç
  • thyroid carcinoma
    °©»ó¼±¾ÏÁ¾(¡­äßðþ)
  • coagulation factors
    ÀÀ°íÀÎÀÚ(¡­ì×í­)
  • exogenous factors
    ¿ÜÀμº ¿ä¼Ò(èâì×àõ é©áÈ).
  • exogenous factors
    ¿ÜÀμº ¿ä¼Ò(¡­é©áÈ).
  • factors
  • psychological factors affecting medical condition
    ÀÇÇÐÀû»óÅ¿¡ ¿µÇâÀ» ÁÖ´Â ½É¸®Àû ¿ä¼Ò.
  • psychological factors affecting physical condition
    ½Åü»óÅ¿¡ ¿µÇâÀ» ÁÖ´Â ½É¸®Àû ¿ä¼Ò.
  • quality factors
    Ư¼º ¿ä¼Ò, Áú ¿ä¼Ò
  • tissue growth factors
  • absolute risk
    Àý´ëÀ§Çè
  • absolute risk model
    Àý´ëÀ§Çè¸ðµ¨
  • acceptable risk
    ¿ëÀÎÀ§Çèµµ, ¼ö¿ëÀ§Çèµµ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • Thyroid gland
    °©»ó»ù
    [¿¾ ¿ë¾î] °©»ó¼±
  • Thyroid gland
    °©»ó»ù [¹æÆÐ»ù]
    [¿¾ ¿ë¾î] °©»ó¼±
  • Isthmus of thyroid gland
    °©»ó»ùÀß·è
    [¿¾ ¿ë¾î] °©»ó¼±ÇùºÎ
  • Pretracheal thyroid gland
    ±â°ü¾Õ°©»ó»ù
    [¿¾ ¿ë¾î] ±â°üÀü°©»ó¼±
  • Accessory thyroid glands
    µ¡°©»ó»ù
    [¿¾ ¿ë¾î] ºÎ°©»ó¼±
  • Thyroid articular surface
    ¹æÆÐ°üÀý¸é
    [¿¾ ¿ë¾î] °©»ó°üÀý¸é
  • THYROID CARTILAGE
    ¹æÆÐ¿¬°ñ [°©»ó¿¬°ñ]
    [¿¾ ¿ë¾î] °©»ó¿¬°ñ
  • Retrosternal thyroid gland
    º¹Àå»ÀµÚ°©»ó»ù
    [¿¾ ¿ë¾î] Èä°ñÈİ©»ó¼±
  • Inferior thyroid artery
    ¾Æ·¡°©»óµ¿¸Æ
    [¿¾ ¿ë¾î] Çϰ©»ó¼±µ¿¸Æ
  • Superior thyroid artery
    À§°©»óµ¿¸Æ
    [¿¾ ¿ë¾î] »ó°©»ó¼±µ¿¸Æ
  • Lingual thyroid gland
    Çô°©»ó»ù
    [¿¾ ¿ë¾î] ¼³°©»ó¼±
  • Azygous thyroid plexus
    Ȧ°©»óÁ¤¸Æ¾ó±â
    [¿¾ ¿ë¾î] ±â°©»ó¼±Á¤¸ÆÃÑ
  • Thyroid lymph nodes
    °©»ó»ù¸²ÇÁÀý
    [¿¾ ¿ë¾î] °©»ó¼±ÀÓÆÄÀý
  • Thyroid diverticulum
    °©»ó»ù½Ï
    [¿¾ ¿ë¾î] °©»ó¼±·Ú
  • Thyroid hormone deficiency (Cretinism)
    °©»ó»ùÈ£¸£¸ó°áÇÌ (°©»ó»ù³­ÀåÀÌ)
    [¿¾ ¿ë¾î] °©»ó¼±È£¸£¸ó°áÇÌ (°©»ó»ù³­ÀåÀÌ)
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 13 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • carcinoma
    ¾ÏÁ¾(äßðú)
  • fibroblast growth factors
    ¼¶À¯¾Æ¼¼Æ÷ ¼ºÀÚÀÎÀÚ (àéë«ä´á¬øàà÷íþì×í­)
  • suppressor factors
    ¾ï¾Ð(ÀÚ) ÀÎÀÚ(åääâ(í­)ì×í­)
  • long-acting thyroid stimulator
    Áö¼Ó¼º(ò¥áÙàõ) °©»ó¼±ÀÚ±ØÁ¦(Ë£ßÒàÍí©Ð½ð­)
  • thyroid colloid
    °©»ó¼±(Ë£ßÒàÍ)ÄÝ·ÎÀ̵å
  • thyroid crisis
    °©»ó¼± Áßµ¶Áõ (Ë£ßÒàÍñéÔ¸ñø)
  • thyroid gland
    °©»ó¼±(Ë£ßÒàÍ)
  • thyroid homones
    °©»ó¼±(Ë£ßÒàÍ) È£¸£¸ó
  • thyroid hyperfunction
    °©»ó¼± ±â´ÉÇ×Áø (Ë£ßÒàÍѦÒöùñòä)
  • thyroid hypofunction
    °©»ó¼± ±â´ÉÀúÇÏ (Ë£ßÒàÍѦÒöî¸ù»)
  • thyroid-stimulating hormone
    °©»ó¼±ÀÚ±Ø (Ë£ßÒàÍí©Ð½) È£¸£¸ó
  • thyroid-stimulating hormone releasing hormone
    °©»ó¼±ÀÚ±Ø (Ë£ßÒàÍí©Ð½) È£¸£¸ó À¯¸®(ë´×î)È£¸£¸ó
  • thyroid storm
    °©»ó¼± ±ÞÁõ (Ë£ßÒàÍÐáñø)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • quality factors
    Ư¼º¿ä¼Ò, Áú¿ä¼Ò
  • high risk group
    °íÀ§Çèµµ±º
  • radiation risk
    ¹æ»ç¼±À§ÇØ, ¹æ»ç¼±À§Çè
  • risk
    À§Çè(µµ), À§Ç輺
  • risk factor
    À§Çè¿äÀÎ
  • functioning thyroid nodule
    ±â´É¼º°©»ó¼± °áÀý
  • intrathoracic thyroid
    Èä°­³»°©»ó¼±
  • isthmus of thyroid gland
    °©»ó¼±ÇùºÎ
  • superior thyroid notch
    »ó°©»óÀýÈç
  • thyroid
    °©»ó¼±ÀÇ, °©»ó¼±
  • thyroid cartilage
    °©»ó¿¬°ñ
  • thyroid function test
    °©»ó¼±±â´É°Ë»ç
  • thyroid gland
    °©»ó»ù, °©»ó¼±
  • thyroid hormone
    °©»ó¼±È£¸£¸ó
  • adenoid cystic carcinoma
    ¼±¾ç³¶¼º¾ÏÁ¾
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
ACC accommodation; acetyl coenzyme A carboxylase; acinic cell carcinoma; acute care center; adenoid cyst...
CDSRF chronic disease and sociodemographic risk factors
CSPINE corticosteroid use, seropositive RA, peripheral joint destruction, involvement of cervical nerves, n...
AR absolute risk; accounts receivable; achievement ratio; actinic reticuloid [syndrome]; active resista...
CRI Cardiac Risk Index; catheter-related infection; chronic renal insufficiency; chronic respiratory ins...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
ATC Anaplastic thyroid carcinoma
DTC Differentiated Thyroid Carcinoma
FMTC Familial Medullary Thyroid Carcinoma
FTC Follicular thyroid carcinoma
MTC Medullary Thyroid Carcinoma
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • controlling factors in facial growth
    ¾È¸é ¼ºÀåÀÇ Á¶Àý ¿äÀÎ
  • carcinoma of thyroid
    °©»ó¼± ¾Ï
    º´¸®Á¶Á÷ÇÐÀûÀ¸·Î À¯µÎ¼± ¾Ï, ¿©Æ÷¼± ¾Ï, ¼ö¾ç ¾Ï, ¹ÌºÐÈ­ ¾Ï ¹× °©»ó¼± ¿ø¹ßÀÇ ¾Ç¼º ¸²ÇÁÁ¾À¸·Î ³ª´µ¾î Áø´Ù. °©»ó¼± ¾ÏÀº º´¸®Á¶Á÷ÀÇ Çü¿¡µû¶ó¼­ ³ªÅ¸³ª´Â ¸ð¾ç, Ä¡·á ¹æÄ§, ¿¹Èİ¡ µÎµå·¯Áö°Ô ´Ù¸£´Ù. ºÐÈ­ ¾ÏÀº °©»ó¼±°ú ¼Ò¼Ó ¸²ÇÁÀýÀÇ ¹üÀ§°¡ ±¹ÇѵǾî ÀÖ´Â °ÍÀÌ ´ëºÎºÐÀε¥ Æó³ª »ÀÀÇ ÀüÀ̸¦ °¡Á®¿À´Â °Íµµ ÀÖ´Ù. ¹ÌºÐÈ­¾ÏÀº ¹æ»ç¼± Á¶»ç¿Í Ç×¾ÏÁ¦¸¦ »ç¿ëÇÏ°í ¾Ç¼º ¸²ÇÁÁ¾¿¡´Â ¹æ»ç¼± Á¶»ç°¡ È¿°úÀûÀÌ´Ù.
  • thyroid carcinoma
    °©»ó¼± ¾Ï
    50´ëÀÇ ¿©¼º¿¡°Ô ÈçÈ÷ ³ªÅ¸³ª´Â °©»ó¼±ÀÇ ¾ÏÁ¾.
  • absolute risk
    Àý´ë À§Çè
  • anesthetic risk
    ¸¶Ãë À§Çèµµ
  • benefit/risk ratio
    À¯ÀÍ/À¯ÇØ ºñÀ²
  • coronary risk factor
    °ü»ó µ¿¸Æ Áúȯ À§Çè ¿äÀÎ
  • explosion risk
    Æø¹ß À§Ç輺
  • high risk group
    °íÀ§Çèµµ±º
  • operative risk
    ¼ö¼ú À§Çèµµ
  • risk
    À§Çè, À§Çèµµ, À§Ç輺
  • risk factor
    À§Çè ¿äÀÎ, À§Çè ¿ä¼Ò, À§Çè ÀÎÀÚ
    °³ÀÎÀ̳ª ´Üü°¡ ÁúȯÀ̳ª Àå¾Ö¿¡ °É¸®±â ½±°Ô ÇÏ´Â ¿øÀÎÀÌ µÇ´Â ¿ä¼Ò·Î¼­ ¹Î°¨ÇÑ »ç¶÷µé¿¡¼­ ¹ß»ý ºóµµ¿Í Á¤µµ¸¦ Áõ°¡½ÃŲ´Ù.
  • risk management
    ¼úÀÚÀÇ ¾ÈÀü ¼öÄ¢
  • risk principle
    À§Çèµµ ¿ø¸®
  • aberrant thyroid
    ÀÌ»ó °©»ó¼±, ¹ÌÀÔ °©»ó¼±
    Á¤»óÀûÀÎ ºÎÀ§°¡ ¾Æ´Ñ ´Ù¸¥ °÷¿¡ À߸ø µé¾î°£ °©»ó¼± Á¶Á÷.
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
thyroid carcinoma risk factors <radiology> Increased risk of malignancy: young female, male, history of radiation to head or neck, hard lesion, other neck masses, no shrinkage on TSH, family hx of thyroid carcinoma see: thyroid carcinoma
(12 Dec 1998)
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
oesophageal carcinoma risk factors <radiology> P Plummer-Vinson Web, A achalasia, alcohol, B Barrett oesophagus, S stricture, T tylosis, tobacco see: oesophageal carcinoma
(12 Dec 1998)
glaucoma, risk factors If you belong to a high-risk group for glaucoma, have your eyes examined through dilated pupils every 2 years by an eye care professional. High-risk groups include everyone with a family history of glaucoma, everyone over the age of 60 and any Black over the age of 40. (Among Blacks, studies show that glaucoma is: 5 times more likely to occur in Blacks than in Whites and about 4 times more likely to cause blindness in Blacks than in Whites).
(12 Dec 1998)
risk factors An aspect of personal behaviour or lifestyle, environmental exposure, or inborn or inherited characteristic, which, on the basis of epidemiologic evidence, is known to be associated with a health-related condition considered important to prevent.
(12 Dec 1998)
anaplastic carcinoma of the thyroid <oncology, tumour> An aggressive form and rare form of thyroid cancer that is one of the most rapidly growing and invasive types of thyroid cancer.
It commonly occurs in people over 60 years of age and may cause obstruction of the trachea. The cause is unknown but exposure to radiation may be a factor.
Thyroid function tests are usually normal. Hoarse voice, cough and coughing up blood are common symptoms. Examination may reveal nodules in the thyroid gland.
Diagnosis is made via biopsy. Treatment is surgical with or without radiation therapy.
(27 Sep 1997)
giant cell carcinoma of thyroid gland A rapidly progressive undifferentiated carcinoma observed in the thyroid gland, characterised by numerous, unusually large, anaplastic cells derived from glandular epithelium of the thyroid gland.
(05 Mar 2000)
thyroid carcinoma <radiology> Papillary-follicular (75%), well-differentiated, 95% 5-yr survival with treatment, papillary may lead to neck nodes, follicular may lead to lungs, bone (haematogenous), anaplastic (20%), older patients, prognosis poor, medullary (5%), C cells, associated with pheochromocytoma (MEN-2 and MEN-3) see also: hot and cold nodules on radionuclide studies, risk factors
(12 Dec 1998)
lateral aberrant thyroid carcinoma <tumour> A cervical nodule of thyroid carcinoma situated outside the thyroid gland, formerly thought to arise from ectopic thyroid tissue but now believed to be metastatic from an occult carcinoma within the gland.
(05 Mar 2000)
absolute risk <statistics> The excess risk due to exposure to a specific hazard (disease, injury, etc.)
(15 Jan 1998)
acceptable risk <statistics> This relates to the potential for suffering disease or injury that will be tolerated by an individual, group, or society in exchange for the benefits of using a substance or process that will cause such disease or injury.
Acceptability of risk depends on scientific data, social, economic, and political factors, and on the perceived benefits arising from a chemical or process that creates the risk in question.
(15 Jan 1998)
attributable risk The rate of a disease or other outcome in exposed individuals that can be attributed to the exposure.
(05 Mar 2000)
cardiac risk A term to describe overall risk of developing heart disease (blockage of the coronary arteries). Typical risk factors include: diabetes, high blood pressure, prior heart attack, high cholesterol, obesity, smoking and a family history for heart attacks in parents or siblings.
(27 Sep 1997)
recurrence risk In medical genetics, the recurrence risk is the chance that a genetic (inherited) disease present in the family will recur in that family and affect another person (or persons). It is the chance of lightning striking twice (or thrice, etc.).
(12 Dec 1998)
relative risk <epidemiology> The proportion of diseased people amongst those exposed to the relevant risk factor divided by the proportion of diseased people amongst those not exposed to the risk factor. This should be used in those cohort studies where those with and without disease are followed to observe which individuals become diseased.
(05 Dec 1998)
risk The probability that an event will occur. It encompasses a variety of measures of the probability of a generally unfavorable outcome.
(12 Dec 1998)
risk assessment The qualitative or quantitative estimation of the likelihood of adverse effects that may result from exposure to specified health hazards or from the absence of beneficial influences.
(12 Dec 1998)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • carcinoma
    ¾ÏÁ¾(cancer)n
  • thyroid
    °©»ó¼±
  • thyroid
    °©»ó¼±(»ð»ó ¿¬°ñ)(ÀÇ);°©»ó¼±Á¦;¹æÆÐ¸ð¾çÀÇ (¹«´ÌÀÇ);~ cartilage (gland,body)°©»ó ¿¬°ñ(¼±)
  • risk
    À§Çè
  • run a risk
    ¸ðÇèÇÏ´Ù
  • calculated risk
    ¿¹ÃøµÇ´Â À§Çè(½ÇÆÐ)
  • catastrophe risk
    ºñ»ó ÀçÇØ À§Çè
  • country risk
    ±¹°¡º° À§Çèµµ(ÇØ¿Ü À¶ÀÚ¸¦ ÇØÁÙ ¶§ÀÇ À¯ÀÚ ´ë»ó±¹ÀÇ ½Å¿ëµµ)
  • risk
    À§Çè(¼º);¸ðÇè;À§Çè(·ü);º¸Çè±Ý(¾×);ÇǺ¸ÇèÀÚ(¹°);À§Å·ӰÔÇÏ´Ù;¸ðÇèÇÏ´Ù;(À§ÇèµîÀ»)°¢¿ÀÇϰí ÀÖ´Ù;°¨ÇàÇÏ´Ù;°¨È÷...ÇÏ´Ù
  • risk capital
    =VENTURE CAPITAL
  • risk manager
    º¸Çè ´ã´ç ÀÓÁ÷¿ø
  • risk-benefit ratio
    À§Ç輺°ú ¼öÀͼº°úÀÇ ºñÀ²
  • risk-money
    ºÎÁ·±Ý º¸»ó ¼ö´ç(ÀºÇà µî¿¡¼­ Ãâ³³°è¿ø¿¡°Ô ÁÖ´Â)
  • security risk
    (Ä¡¾È»óÀÇ)À§Çè Àι°
  • war risk insurance
    ÀüÀï º¸Çè
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
ÅëÇÕ°Ë»ö ¿Ï·á